Tumour immunogenicity goes with the (mitochondrial electron) flow.

Area of Science:

• Cancer Research
• Immunology
• Mitochondrial Metabolism

Background:

• Mitochondrial metabolism and electron transport chain (ETC) function are critical for tumor growth.
• The influence of ETC function on cancer immunogenicity remains largely unexplored.
• Understanding this link can reveal novel therapeutic strategies.

Purpose of the Study:

• To investigate the impact of inhibiting mitochondrial complex II on tumor immunogenicity.
• To elucidate the mechanisms underlying the observed anti-tumor effects.
• To explore the potential of modulating mitochondrial function for cancer therapy.

Main Methods:

• Inhibition of mitochondrial complex II in tumor models.
• Assessment of tumor immunogenicity and T-cell-mediated cytotoxicity.
• Analysis of succinate levels and histone methylation.
• Evaluation of major histocompatibility complex-antigen processing and presentation (MHC-APP) gene expression.

Main Results:

• Inhibition of complex II enhanced tumor immunogenicity and T-cell cytotoxicity.
• Succinate accumulation due to complex II inhibition affected histone methylation.
• Histone methylation led to increased MHC-APP gene expression, independent of interferon signaling.
• These changes resulted in significant tumor growth inhibition.

Conclusions:

• Modulating mitochondrial electron flow, specifically by inhibiting complex II, can enhance tumor immunogenicity.
• Succinate accumulation and subsequent histone methylation are key mediators of this effect.
• This approach offers a promising therapeutic avenue, particularly for tumors with compromised MHC-APP expression or interferon signaling.